Kalaris (KLRS) Director Laurie Keating Receives 18,000-Share Award

What Happened
Laurie Keating, a director of Kalaris Therapeutics, was granted a derivative award on Aug 1, 2026 representing 18,000 shares. The grant is reported at a $0.00 acquisition price (i.e., an equity award/option rather than a cash purchase), so there was no immediate cash outlay or sale.

Key Details

• Transaction date: 2026-08-01; Form 4 filed: 2026-08-03 (timely filing).
• Transaction type/code: Award/Grant (A) — derivative equity award for 18,000 shares; price shown $0.00.
• Vesting: Shares underlying the option vest in equal monthly installments over three years from Aug 1, 2026 through Aug 1, 2029, subject to continuous service (footnote F1).
• Shares owned after transaction: Not disclosed in the filing.
• No exercise, sale, or tax-withholding event reported in this transaction.

Context
This was a grant of an equity award (common for directors/exec compensation), not an open‑market purchase or sale. As a derivative award, it provides the right to acquire shares over time if vesting conditions are met; it does not indicate an immediate change in market exposure from buying or selling stock.